Iridex Corp and Imperial College Healthcare NHS Trust in London announced the first patient enrolment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulseTransscleral Laser Therapy (TLT) using Iridex’ Cyclo G6 Laser and the MicroPulse P3 delivery device.
Related: Axena begins study to explore barriers to UI treatment for women
According to the company, the partnership establishes a large-scale enrolment platform to advance clinical research.
“The first patient enrolment in this partnership with Imperial College Healthcare NHS Trust is the first step toward multicenter participation enabling a large-scale view and significant in-country impact of our MicroPulsetechnology,” David I. Bruce, president and CEO of Iridex, said in a news release.
The company noted in its news release the study, titled “MicroPulse Transscleral Laser Therapy: A Prospective UK Study,” is set to expand Iridex’s global clinical portfolio, through its commitment to funding essential components of the 3-year study and providing a custom-designed and secure database management system.
Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, emphasized the importance of rapid expansion.
“We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma. Expansion to include other units will be crucial in advancing glaucoma treatment in the UK,” Bloom said in the news release. “Our partnership with Iridex is key to enhancing this study’s reach and impact.”
Moreover, the company noted in the news release the Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulseTLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. The registry and study is structured for expanded participation from other UK providers to join the program and build enrolment for large patient cohorts.
Iridex and Imperial College Healthcare NHS Trust are focused on running the study in line with the strictest ethical and regulatory standards and look forward to welcoming additional sites to join the program. The collaboration highlights the company’s shared vision for advancing medical science with MicroPulse TLT. It promises significant insights and advancements in glaucoma laser therapy, potentially revolutionizing treatment approaches and enhancing patient care.
Iridex noted clinical trial training, service, and support is being provided by Chesham, England-based Carleton Optical Equipment Ltd.
